BioCentury
ARTICLE | Clinical News

Ranexa: Phase III data

April 26, 2004 7:00 AM UTC

Previously reported result from the Phase III MARISA trial in 191 angina patients showed Ranexa increased symptom-limited exercise duration (p<0.005). Ranexa also increased the secondary endpoint of t...